Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Lucas MorenoRebekah WestonCormac OwensDominique Valteau-CouanetMarion GambartVictoria CastelChristian Michel ZwaanKarsten NysomNicolas U GerberAurora CastellanoGenevieve LaureysRuth Lydia LadensteinJochen RösslerGuy MakinDermot MurphyBruce MorlandSucheta J VaidyaEstelle ThebaudNatasha K A Van EijkelenburgDeborah A TweddleGiuseppe BaroneJulie TandonnetNadège CorradiniPascal ChastagnerCatherine PaillardFrancisco J Bautista SirventSoledad Gallego MelconBram De WildeLynley MarshallJuliet GraySusan Ann BurchillGudrun SchleiermacherLouis CheslerAndrew C PeetMartin O LeachKieran McHughRoisin HayesNeil Peter JeromeHubert CaronJennifer LaidlerNicola FenwickGrace HoltVeronica MorozPamela R KearnsSimon GatesAndrew D J PearsonKeith Wheatleynull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The addition of B met protocol-defined success criteria for ORR and appeared to improve PFS. Within this phase II trial, BIT showed signals of antitumor activity with acceptable tolerability. Future trials will confirm these results in the chemoimmunotherapy era.
Keyphrases